Cantitate/Preț
Produs

Quantitative Evaluation of Safety in Drug Development: Design, Analysis and Reporting: Chapman & Hall/CRC Biostatistics Series

Editat de Qi Jiang, H. Amy Xia
en Limba Engleză Hardback – 8 dec 2014
State-of-the-Art Methods for Drug Safety Assessment
Responding to the increased scrutiny of drug safety in recent years, Quantitative Evaluation of Safety in Drug Development: Design, Analysis and Reporting explains design, monitoring, analysis, and reporting issues for both clinical trials and observational studies in biopharmaceutical product development. It presents the latest statistical methods for drug safety assessment.
The book’s three sections focus on study design, safety monitoring, and data evaluation/analysis. The book addresses key challenges across regulatory agencies, industry, and academia. It discusses quantitative approaches to safety evaluation and risk management in drug development, covering Bayesian methods, effective safety graphics, and risk-benefit evaluation.
Written by a team of experienced leaders, this book brings the most advanced knowledge and statistical methods of drug safety to the statistical, clinical, and safety community. It shares best practices and stimulates further research and methodology development in the drug safety area.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 31243 lei  6-8 săpt.
  CRC Press – 30 iun 2020 31243 lei  6-8 săpt.
Hardback (1) 79034 lei  6-8 săpt.
  CRC Press – 8 dec 2014 79034 lei  6-8 săpt.

Din seria Chapman & Hall/CRC Biostatistics Series

Preț: 79034 lei

Preț vechi: 96383 lei
-18% Nou

Puncte Express: 1186

Preț estimativ în valută:
15125 15771$ 12570£

Carte tipărită la comandă

Livrare economică 20 martie-03 aprilie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9781466555457
ISBN-10: 1466555459
Pagini: 382
Ilustrații: 44 black & white illustrations, 26 black & white tables
Dimensiuni: 156 x 234 x 25 mm
Greutate: 0.68 kg
Ediția:1
Editura: CRC Press
Colecția Chapman and Hall/CRC
Seria Chapman & Hall/CRC Biostatistics Series


Cuprins

Study Design. Safety Monitoring. Evaluation/Analysis. Index.

Notă biografică

Qi Jiang, PhD, is an executive director of Global Biostatistical Science at Amgen Inc. Dr. Jiang is a fellow of the American Statistical Association, a member of many industry-wide initiatives, and an associate editor of the journal Statistics in Biopharmaceutical Research (SBR). She has over 18 years of clinical trial experience in early and late clinical development phases across a broad spectrum of therapeutic areas. Her research interests include drug safety monitoring and analyses, benefit-risk assessment, clinical meaningfulness, dichotomization, meta-analyses, network meta-analysis, adaptive design, and non-inferiority study design and analyses.
H. Amy Xia, PhD, is an executive director of Global Biostatistical Science at Amgen Inc. Dr. Xia is a member of many industry-wide initiatives. In the past 18 years, she has worked on designing, executing, and reporting clinical trials as well as observational studies for developing pharmaceutical and medical device products in a wide range of different disease areas. Her research interests include safety biostatistics, signal detection, Bayesian design, monitoring and analysis of clinical trials, meta-analysis, and adaptive design.

Descriere

Written by a team of experienced leaders, this book brings the most advanced knowledge and statistical methods of drug safety to the statistical, clinical, and safety community. It explains design, monitoring, analysis, and reporting issues for both clinical trials and observational studies in biopharmaceutical product development. The book addresses key challenges across regulatory agencies, industry, and academia. It discusses quantitative approaches to safety evaluation and risk management in drug development, covering Bayesian methods, effective safety graphics, and risk-benefit evaluation.